DexCom, Inc. Forecast, price target & analysts
DexCom, Inc. Target price 2026 - Analyst rating & recommendation
DexCom, Inc. Classifications & Recommendation
DexCom, Inc. Price Target
| Target Price | $95.88 |
| Price | $84.30 |
| Potential | 13.74% |
| Number of Estimates | 29 |
| 29 Analysts have issued a price target DexCom, Inc. 2027 . The average DexCom, Inc. target price is $95.88. This is 13.74% higher than the current stock price. The highest price target is $120.75 43.24% , the lowest is $75.75 10.14% . | |
| A rating was issued by 36 analysts: 31 Analysts recommend DexCom, Inc. to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the DexCom, Inc. stock has an average upside potential 2027 of 13.74% . Most analysts recommend the DexCom, Inc. stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2030
32 Analysts have issued a sales forecast DexCom, Inc. 2026 . The average DexCom, Inc. sales estimate is
This results in the following potential growth metrics:
27 Analysts have issued an DexCom, Inc. EBITDA forecast 2026. The average DexCom, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 DexCom, Inc. Analysts have issued a net profit forecast 2026. The average DexCom, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030
32 Analysts have issued a DexCom, Inc. forecast for earnings per share. The average DexCom, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Current DexCom, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 01 2026 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Sep 18 2026 |
| TD Cowen |
Buy
➜
Buy
|
Unchanged | Sep 18 2026 |
| Argus Research |
Buy
➜
Buy
|
Unchanged | Aug 04 2026 |
| Canaccord Genuity |
Buy
➜
Buy
|
Unchanged | Aug 03 2026 |
| Citigroup |
Buy
➜
Buy
|
Unchanged | Jul 31 2026 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Jul 31 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 01 2026 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Sep 18 2026 |
|
Unchanged
TD Cowen:
Buy
➜
Buy
|
Sep 18 2026 |
|
Unchanged
Argus Research:
Buy
➜
Buy
|
Aug 04 2026 |
|
Unchanged
Canaccord Genuity:
Buy
➜
Buy
|
Aug 03 2026 |
|
Unchanged
Citigroup:
Buy
➜
Buy
|
Jul 31 2026 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Jul 31 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
